Talicia is an anti-infection drug owned by Redhill. It is a combination of Amoxicillin, Omeprazole Magnesium, and Rifabutin released in the form of a delayed release oral capsule. Talicia was first authorized for market use on 01 November, 2019 and presently holds a total of 5 drug patents, none of which have expired to date.
The generic version of Talicia is anticipated to be available after 12 February, 2034. This is following the expiration of the last patent, US9498445, titled 'Pharmaceutical compositions for the treatment of Helicobacter pylori'. The other patents supporting Talicia also expire on the same date.
Talicia is primarily used to treat H. pylori infections in adults. Its active ingredients, Amoxicillin and Rifabutin, have antibiotic properties that inhibit the growth of bacteria, while Omeprazole Magnesium reduces the production of stomach acid aiding in the overall effectiveness of the treatment.
Talicia, owned by Redhill, is protected by 5 patents; the latest of these expires on 12 February, 2034. The patents encompass pharmaceutical compositions for the treatment of H. pylori. For more in-depth information about the availability of Talicia generic, see the details of the patents below: